Safety and tolerability of ex vivo TKD/IL-2 stimulated, autologous NK cells have been demonstrated in patients with metastasized colorectal and NSCLC in a Phase I clinical trial (72). This evidence concerns the gene IL2 and non-small cell lung carcinoma.